Healthcare solutions company Evolent Health (NYSE:EVH) will be reporting results this Thursday after the bell. Here’s what investors should know.
Evolent Health beat analysts’ revenue expectations by 4.9% last quarter, reporting revenues of $483.6 million, down 24.4% year on year. It was a mixed quarter for the company, with full-year revenue guidance slightly topping analysts’ expectations but a significant miss of analysts’ EPS estimates.
Is Evolent Health a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Evolent Health’s revenue to decline 29% year on year to $459.5 million, a reversal from the 37.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.08 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Evolent Health has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Evolent Health’s peers in the healthcare technology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Omnicell delivered year-on-year revenue growth of 5%, beating analysts’ expectations by 4.9%, and Hims & Hers Health reported revenues up 72.6%, falling short of estimates by 1.1%. Omnicell’s stock price was unchanged after the resultswhile Hims & Hers Health was down 12.5%.
Read our full analysis of Omnicell’s results here and Hims & Hers Health’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Evolent Health is down 18.4% during the same time and is heading into earnings with an average analyst price target of $15.31 (compared to the current share price of $9.50).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.